Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized study of adagrasib plus cetuximab versus chemotherapy in KRAS G12C-mutated advanced colorectal cancer after progression on first-line therapy
CTR20220199Phase 3Active
- Sponsor
- Mirati Therapeutics
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of adagrasib, cetuximab in colorectal cancer (CRC), sponsored by Mirati Therapeutics. Started Jun 2022; status: active.
02
Drugs
adagrasibcetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20220199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220199.